United States: Antitrust Alert: New FTC Pharma Patent Litigation Report Finds Increase In "Reverse Payment" Settlements Based On Expanded Definition Of "Payments"

With the Supreme Court set to address the validity of "reverse payment" settlements of pharmaceutical patent litigation, the FTC released a summary of its new report, announcing that in 2012 drug companies entered "a record number" of such settlements. However, the underlying data and analysis merely highlight that the devil is in the definitions:over time the FTC has expanded its definition of the term "payments."Unless the Supreme Court moots this issue in FTC v. Watson Pharmaceuticals, 677 F.3d 1298 (11th Cir. 2012), cert. granted, 568 U.S. ___(U.S. Dec. 7, 2012) (No. 12-416), this far-reaching definition of "payment" may become the next critical front in the FTC's campaign against "reverse payment" settlements. 

The Dispute Over Reverse Payments 

In a "reverse payment" settlement (in the FTC's vernacular, a "pay-for-delay" settlement), the branded-drug manufacturer settles a challenge to its patent by providing compensation to the generic challenger. In exchange, the generic manufacturer typically agrees to drop its patent challenge and enter the market as a licensee at some later time before the patent expires. Since roughly 2000, the FTC has engaged in a largely unsuccessful effort to persuade courts that such settlements should be presumed unlawful, whether or not the generic drug infringed the subject patent. After failing in the Second, Eleventh, and Federal Circuits, the FTC finally persuaded the Third Circuit in 2012 to accept its view, which created the circuit split soon to be resolved by the Supreme Court in Watson

The FTC's 2012 "Overview" 

The new FTC report, entitled "Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2012," is the latest in a series of annual reports, which commenced in 2004 after Congress required all pharmaceutical patent settlements with generic challengers to be filed with the FTC.  For the last three fiscal years the FTC has provided only brief "overviews" of the actual report (the last full version of such an annual report released by the FTC was for FY2009). The 2012 overview emphasizes two points.  First, the report states that, in 2012, branded and generic drug companies entered 40 settlements "that potentially involve pay-for-delay payments," which is the highest annual figure since the FTC began collecting such data in 2003. According to the report, these 40 settlements "potentially involve pay for delay because they contain compensation to the generic manufacturer and a restriction on the generic manufacturer's ability to market its product."  Second, although the report does not disclose the nature of the compensation in 21 of those agreements, it states that, in 19 of these 40 agreements, "compensation took the form of a brand manufacturer's promise not to market an authorized generic...for some period."  This form of compensation thus includes any agreement that gives the generic manufacturer an exclusive license to sell a generic version of the drug for a period of time.

While the report states that both of these developments are record-setting, these conclusions depend on the FTC's extension of the definition of "payment."  In its original challenges to "reverse payment" settlements, the FTC stressed that monetary payments warrant antitrust scrutiny.  See, e.g., In re Schering-Plough Corp., 136 F.T.C. 956, 987  (F.T.C. 2003), rev'd sub nom. Schering-Plough Corp. v. FTC, 402 F.3d 1056 (11th Cir. 2005) ("A settlement agreement is not illegal simply because it delays generic entry until some date before expiration of the pioneer's patent....  [T]he payment of money by Schering ... is what makes this case different.").  Over time, the FTC expanded its understanding of "payment" to mean "some form of compensation" (including "agreements with incentives for a branded company not to launch an authorized generic product").  See FTC, Summary of Agreements Filed in FY 2008, at 1, n.2.  In a recent amicus brief, the FTC argued that the definition of "payment" encompasses any "valuable thing" exchanged. See Brief for FTC as Amicus Curiae, In Re Lamictal Direct Purchaser Antitrust Litig., 2012 WL 6725580 (D.N.J., Dec. 6, 2012) at 10, n.29 (emphasis in original).   

Without such an expanded definition of "payments," the FTC would be hard-pressed to maintain that reverse payments still occur, because – based on our experience and a careful reading of the FTC's annual reports – no Hatch-Waxman settlement has included a direct monetary payment in over a decade.  (Few are willing to risk the burden of an FTC investigation, even if they would ultimately prevail in court.) On the other hand, dozens of such settlements have provided the generic with an exclusive license for some period of time. 


1)    The FTC's current definition of "payment" – meaning "some form of compensation" or any "valuable thing" – could include, it seems, every type of consideration available in a patent-litigation settlement, such as allowing an early entry date, a low royalty to the patent-holder, a beneficial field of use restriction, or a compromise on a damages claim – as well as paying cash or providing an exclusive license. Since all patent settlements convey "value" to both parties, the FTC's definition threatens to make all patent-litigation settlements involve "reverse payments," which in turn would mean that all patent settlements are presumptively anticompetitive.  The FTC's position thus raises the stakes in the Supreme Court's forthcoming decision in Watson because, even if the FTC continues to approve of settlements that merely split the remaining patent life, private plaintiffs may not interpret the law in the same way. 

2)    Despite the FTC's current, far-reaching definition of "payment," the FTC itself has never challenged a settlement merely because the branded-drug manufacturer agreed not to release an authorized generic (which, as noted above, is indistinguishable from granting a wholly exclusive license). For the FTC, bringing such a case undoubtedly would be an uphill battle, given the established rule that antitrust law does not prohibit "a restraint of commerce that may arise from reasonable and legal conditions imposed upon the ... licensee of a patent."  Bement v. Nat'l Harrow Co., 186 U.S. 70, 92 (1902).

3)    Nevertheless, in the recent amicus brief discussed above, the FTC argued that by agreeing not to release an authorized generic – thereby granting an "exclusive license" to the generic manufacturer – a branded-drug manufacturer engaged in a "reverse payment" settlement that should be deemed presumptively anticompetitive under the Third Circuit's recent decision in In re K-Dur Antitrust Litigation, 686 F.3d 197 (3d Cir. 2012).  The district court rejected the FTC's position, holding "that the term 'reverse payment' is not sufficiently broad to encompass any benefit ... to [the generic] in a negotiated settlement."  In Re Lamictal Direct Purchaser Antitrust Litig., 2012 WL 6725580, at *6 (D.N.J., Dec. 6, 2012). 

4)    Finally, the Supreme Court's Watson opinion may provide the final word on this topic and on many other aspects of "reverse payment" settlements as early as June 2013.  Stay tuned. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions